Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England

Open access

Preprint — published as 10.1136/bmj.n1088 · Paper page

Abstract

Objectives: To estimate the real-world effectiveness of the Pfizer/BioNTech BNT162b2 vaccine and Astrazeneca ChAdOx1 vaccine against Confirmed COVID-19, hospitalisations and deaths. To estimate effectiveness on the UK variant of concern. Design: Test negative case control design Setting: Community COVID-19 PCR testing in England Participants: All adults in England aged 70 years and older (over 7.5 million). All COVID-19 testing in the community among eligible individuals who reported symptoms between 8 th December 2020 and 19 th February 2021 was included in the analysis. Interventions: One and two doses of BNT162b2 vaccine. One dose of ChAdOx1 vaccine. Main outcome measures: Symptomatic PCR confirmed SARS-CoV-2 infection, hospitalisations and deaths with COVID-19. Results: Individuals aged >=80 years vaccinated with BNT162b2 prior to 4 th January, had a higher odds of testing positive in the first 9 days after vaccination (odds ratio up to 1.48, 95%CI 1.23-1.77), indicating that those initially targeted had a higher underlying risk of infection. Vaccine effectiveness was therefore estimated relative to the baseline post-vaccination period. Vaccine effects were noted from 10-13 days after vaccination, reaching an effectiveness of 70% (95% CI 59-78%) from 28-34 days, then plateauing. From 14 days after the second dose a vaccine effectiveness of 89% (95%CI: 85-93%) was seen. Individuals aged >=70 years vaccinated from 4 th January had a similar underlying risk of COVID-19 to unvaccinated individuals. With BNT162b2, vaccine effectiveness reached 61% (95%CI 51-69%) from 28-34 days after vaccination then plateaued. With the ChAdOx1 vaccine, vaccine effects were seen from 14-20 days after vaccination reaching an effectiveness of 60% (95%CI 41-73%) from 28-34 days and further increasing to 73% (95%CI 27-90%) from day 35 onwards. On top of the protection against symptomatic disease, cases who had been vaccinated with one dose of BNT162b2 had an additional 43% (95%CI 33-52%) lower risk of emergency hospitalisation and an additional 51% (95%CI 37-62%) lower risk of death. Cases who had been vaccinated with one dose of ChAdOx1 had an additional 37% (95% CI 3-59%) lower risk of emergency hospitalisation. There was insufficient follow-up to assess the effect of ChAdOx1 on mortality due to the later rollout of this vaccine. Combined with the effect against symptomatic disease, this indicates that a single dose of either vaccine is approximately 80% effective at preventing hospitalisation and a single dose of BNT162b2 is 85% effective at preventing death with COVID-19. Conclusion: Vaccination with either a single dose of BNT162b2 or ChAdOx1 COVID-19 vaccination was associated with a significant reduction in symptomatic SARS-CoV2 positive cases in older adults with even greater protection against severe disease. Both vaccines show similar effects. Protection was maintained for the duration of follow-up (>6 weeks). A second dose of BNT162b2 provides further protection against symptomatic disease but second doses of ChAdOx1 have not yet been rolled out in England. There is a clear effect of the vaccines against the UK variant of concern.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2021.03.01.21252652

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC BY-NC · PubMed Central
Fig 1 Number of cases and controls by interval from vaccination with Pfizer-Biontech BNT162b2 and Oxford Astra-Zeneca ChAdOx1-S vaccines
Fig 1 Number of cases and controls by interval from vaccination with Pfizer-Biontech BNT162b2 and Oxford Astra-Zeneca ChAdOx1-S vaccinesCC BY-NC · PubMed Central
Fig 2 Adjusted odds ratios for confirmed cases of covid-19 by interval after vaccination with Pfizer-BioNTech BNT162b2 before 4 January 2021 in those aged 80 years and older
Fig 2 Adjusted odds ratios for confirmed cases of covid-19 by interval after vaccination with Pfizer-BioNTech BNT162b2 before 4 January 2021 in those aged 80 years and olderCC BY-NC · PubMed Central
Fig 3 Adjusted odds ratios for confirmed cases of covid-19 by interval after vaccination with Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S from 4 January 2021
Fig 3 Adjusted odds ratios for confirmed cases of covid-19 by interval after vaccination with Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S from 4 January 2021CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 3

  1. 2020, Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates, New England Journal of Medicine, 383, 2439, 10.1056/NEJMoa2027906 · doi:10.1056/nejmoa2027906 · Paper page
  2. Ramsay M. COVID-19: the green book, chapter 14a. Immunisation against infectious diseases: Public Health England,; 2020.
  3. 2021, Lancet, 396, 1979

Cited by

See all 1,389

Metadata

Authors
Bernal, J. L., Andrews, N., Gower, C., Stowe, J., Robertson, C., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., Brown, K., Cameron, C., Stockton, D., McMenamin, J., & Ramsay, M.
Affiliations
  • Public Health England (GB)
  • University of Strathclyde (GB)
  • Public Health Wales (GB)
  • Public Health Agency (GB)
  • Health Protection Scotland (GB)
Corresponding author
Bernal, Jamie Lopez
Venue
BMJ
Publisher
openRxiv
Published
2021-03-02
Volume
373
Pages
n1088-n1088
ISSN
1756-1833 (ISSN-L)
OpenAlex
W3160138987
Cited by
1,389
References
19
Citations by year
2026: 17 · 2025: 74 · 2024: 183 · 2023: 289 · 2022: 481 · 2021: 342
FWCI
102.76
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ (publishedVersion, cc-by-nc)
  • medRxiv (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion)
Funders
Public Health England
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords
COVID-19 vaccines, BNT162b2, ChAdOx1 nCoV-19 vaccine, vaccine effectiveness, older adults, SARS-CoV-2, COVID-19 hospitalization, COVID-19 mortality, breakthrough infection, B.1.1.7 variant, community-based testing, test-negative case-control, real-world effectiveness, second dose
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, COVID-19 Testing, BNT162 Vaccine, ChAdOx1 nCoV-19, Aged, Aged, 80 and over, England, Female, Hospitalization, Humans, Male, Vaccination, Case-Control Studies, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. https://app.cochat.ai/papers/10.1101/2021.03.01.21252652
The paper
Bernal, J. L., Andrews, N., Gower, C., Stowe, J., Robertson, C., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., Brown, K., Cameron, C., Stockton, D., McMenamin, J., & Ramsay, M. (2021). Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. BMJ. https://doi.org/10.1101/2021.03.01.21252652

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.